Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS

Ionis-Partnered Asset Developed For SOD1 Genetic Mutations

Executive Summary

The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.

You may also be interested in...



Well-Funded Chinese Venture Races To Clinic Amid Reviving CNS Interest

SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.

Amylyx Will Submit ALS Drug For Approval In The Coming Months

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Biogen Says Physician Debate About Aduhelm More ‘Pervasive’ Than Anticipated

CEO Michel Vounatsos and US president Alisha Alaimo outlined plans to overcome the Alzheimer’s drug’s launch challenges and hinted at lower sales expectations at a Morgan Stanley investor event.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel